HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Awareness, early intervention needed to reduce impact of breast cancer-related lymphedema
-
- Abramson Cancer Center appoints deputy director
- Addition of enzalutamide to androgen deprivation beneficial for certain men with prostate cancer
- American Society for Radiation Oncology members receive fellows designation
- ASH selects trainees, junior faculty for research training institute
- Atlantic Health System Cancer Care appoints medical director of gastrointestinal medical oncology
- CAR T-cell therapy approved for B-cell lymphomas may save ‘thousands of lives’ in next few years
- City of Hope announces two faculty appointments
- Duvelisib extends PFS in chronic lymphocytic leukemia, small lymphocytic lymphoma
-
- Fox Chase Cancer Center announces appointments
- Generic oral chemotherapy less cost-effective than anticipated
- The preservation of affordable cancer care John Sweetenham, MD, FRCP, FACP
- FDA approves Mylotarg for treatment of acute myeloid leukemia
- FDA expands approval of Faslodex for advanced breast cancer
- FDA grants fast track designation to MitoGel for upper tract urothelial carcinoma
- FDA grants orphan drug designation to SY-1425 for acute myeloid leukemia
- Blood-based assay superior to PSA for prostate cancer diagnosis
-
- Eltrombopag shows promise as first treatment for severe aplastic anemia
- Percentage of uninsured, newly diagnosed patients with cancer declines after ACA
- Risk-adapted therapeutic strategies effective for early-stage Hodgkin lymphoma
- Screen-detected breast cancers persist without treatment
- TAS-102, bevacizumab promising for refractory colorectal cancer
- Addition of pembrolizumab to chemotherapy improves outcomes in advanced NSCLC
- Annual CT scan does not offer survival benefit for completely resected NSCLC
- Cabozantinib extends PFS as first-line therapy for metastatic renal cell carcinoma
-
- Chemotherapy, radiation underused in initial treatment of limited-stage small-cell lung cancer
- De-escalated radiation safe, effective for HPV-positive oropharyngeal cancer
- Early palliative care does not show quality-of-life benefit for newly diagnosed mesothelioma
- Electronic medical records beneficial during lung cancer screening
- Fruquintinib, gefitinib shows promise for EGFR-mutated non-small cell lung cancer
- HemOnc Today New York to highlight advances in immunotherapy, targeted treatments
- Ipilimumab shows promise in mutated NSCLC, but toxicities may limit use
- Maintenance rucaparib extends PFS in recurrent ovarian cancer
-
- Medicaid expansion cuts uninsured rate by half among patients with cancer
- Osimertinib extends PFS in EGFR-positive lung cancer
- Palliative care, hospice resources underutilized for advanced non-small cell lung cancer
- Pembrolizumab may become standard for advanced gastric cancer
- Pembrolizumab shows promise in metastatic head and neck cancer
- PIK3CA mutation linked to brain metastases in large cell neuroendocrine carcinoma
- Smoking cessation counseling successfully integrates into screening program
- Smoking status does not impact outcomes with anti-PD-1 therapy
-
- Socioeconomic factors influence non-small cell lung cancer survival
- Survey: Breast cancer radiation therapy ‘less scary’ than anticipated
- Should prophylactic antibiotic therapy be used to prevent recurrent infection in patients with lymphedema?